Lorviqua ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

lorviqua

pfizer europe ma eeig - lorlatinib - karcinoma, nesīkšūnu plaušas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Camcevi ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

camcevi

accord healthcare s.l.u. - leuprorelin mesilate - prostatas audzēji - endokrīnā terapija - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Fromilid 125 mg/5 ml granulas iekšķīgi lietojamas suspensijas pagatavošanai লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

fromilid 125 mg/5 ml granulas iekšķīgi lietojamas suspensijas pagatavošanai

krka, d.d., novo mesto, slovenia - klaritromicīns - granulas iekšķīgi lietojamas suspensijas pagatavošanai - 125 mg/5 ml

Fromilid Uno 500 mg ilgstošās darbības tabletes লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

fromilid uno 500 mg ilgstošās darbības tabletes

krka, d.d., novo mesto, slovenia - klaritromicīns - modificētās darbības tablete - 500 mg